ALXN completes AMI Phase II enrollment

Alexion (ALXN) and partner Procter & Gamble (PG) completed enrollment of about 900 patients in a second Phase II trial of its pexelizumab 5G1.1 antibody fragment against complement C5 to treat acute m...